The manna of the Next Generation European funds (NGEU) will soon run out, given that they should have been assigned, in principle, only until last August 31st. A very large percentage, between 75% and 80%, has already been allocated. The stated objective of the European funds, and of the Spanish Recovery, Transformation and Resilience Plan, is to accelerate economic and social recovery after the COVID-19 crisis and to increase the capacity for growth in the medium and long term by increasing productivity.

Over the years, life sciences, ranging from biotechnology to pharmaceuticals, consolidated as the third economic activity in Catalonia, have become one of the pillars for building a new economic model that distances us from the low-wage formula. In essence, it is about promoting activities that generate a lot of added value or, more precisely, much more value per worker. In short, economic activities that allow productivity to increase. An outstanding subject, although there are signs of improvement, as indicated by the Economic Report of Catalonia 2025, a study prepared by the Catalan Chambers of Commerce.